Ovarian cancer, historically challenging to diagnose due to vague early symptoms, often reaches advanced stages before ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Ovarian cancer affects over 22,000 women annually in the U.S., yet only 20% of cases are caught early. With no reliable ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

This year, researchers Megan Shen, PhD, and Mary L. “Nora” Disis, MD, of Fred Hutch Cancer Center and UW Medicine ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

Zupancic, CEO of Baltimore fitness company, died after years of battling ovarian cancer, according to a social media post by ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...